ZVIA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zevia PBC is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has short-term momentum from today's price jump, but the broader technical trend remains bearish and there is no strong proprietary buy signal. I would not commit new money here at this level; the better stance is to wait for a clearer trend reversal and stronger fundamental confirmation.
ZVIA is trading at 1.48 after a 6.52% regular-session gain, with a small pre-market follow-through of 0.36%. Despite the bounce, the technical structure is still weak: MACD histogram is negative and contracting, RSI_6 at 57.4 is neutral, and the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5. Price is sitting near pivot support/resistance at 1.44, with immediate resistance at 1.564 and support at 1.316. The short-term pattern data also points to weak forward returns, suggesting the recent pop may not be durable.
The main positive catalyst is the improving turnaround narrative. Telsey noted better-than-expected Q1 results, including strong volume gains of 20.4%, and said the company is making progress with higher 2026 sales growth guidance. Today's sharp price increase also shows traders are responding positively to the turnaround story. Options positioning is slightly bullish, with puts relatively light versus calls.
The biggest negatives are the still-bearish technical trend, lack of recent news, and reduced FY26 adjusted EBITDA guidance due to higher tariffs and fuel costs. The stock is also showing weak forecasted near-term performance based on similar candlestick patterns. There is no AI Stock Picker or SwingMax buy signal, and hedge funds and insiders are both neutral. No politician or congress trading activity was reported.
No detailed financial snapshot was available because of the data error, but the latest reported quarter was Q1 2026. That quarter was described as better than expected, with volume growth of 20.4% and improved sales growth guidance for 2026. The main offset was softer profitability guidance, as management lowered FY26 adjusted EBITDA expectations because of tariffs and fuel costs.
Recent analyst action was mixed but still constructive: Telsey Advisory lowered its price target to $3 from $5 while maintaining an Outperform rating. The target cut shows caution on valuation and near-term earnings pressure, but the rating and commentary remain positive on the turnaround. Wall Street's pro view is that Zevia is improving operationally and delivering strong volume growth; the con view is that margins remain pressured and the stock has not yet confirmed a durable uptrend.
